XTL Biopharmaceuticals Ltd. XTLB
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -40.95%
- 1 year
- -57.72%
- Market cap
- 3.37M
- EPS (ttm)
- -0.36
- Shares out
- 5.45M
- YTD return
- -40.95%
- 1-year return
- -57.72%
- 50-day average
- 1.84
- 200-day average
- 2.32
- Volume
- 1.78K
- Avg volume
- 6.55K
- Open
- 1.59
- Previous close
- 1.46
- Day's range
- 1.37 – 1.59
- 52-week range
- 1.37 – 4.28
- Beta
- 1.00
Key statistics
- Enterprise value
- 782.33M
- Price / book
- 352.00
- Total cash
- 2.34M
- Return on equity
- -13.07%
Fundamental scorecard
1 of 25 checks passed on XTLB’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Dec 31, 2025.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 25, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | 0.10 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2015 | HC Wainwright & Co. | init | — | Buy |
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- xtlbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on XTLB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Noked Israel Ltd. | 3.65% | 198,888 | 350.04K | Sep 29, 2024 |
| Morgan Stanley | 0.49% | 26,451 | 46.55K | Sep 29, 2024 |
| Rhumbline Advisers | 0.12% | 6,519 | 11.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.16% | 8,903 | 15.67K | Oct 30, 2024 |
